Background: Previous studies have shown that giving other foods while breastfeeding increases the risk of mother-to-child transmission of human immunodeficiency virus (HIV) type 1. The mechanism is speculated to be increased inflammation of the gastrointestinal tract. Methods: In a prospective longitudinal study, we compared fecal calprotectin, a marker of intestinal inflammatory disease, in healthy U.S. infants 0-6 months of age who were exclusively breastfed compared to those given additional liquids or solids. Results: In comparison to infants who were mixed-fed, fecal calprotectin was significantly higher in the exclusively breastfed group (p ϭ 0.01) by a mean of 60 mg/kg (SE ϭ 23). Conclusions: Introducing complementary food does not increase intestinal inflammation according to this marker. Studies to assess fecal calprotectin levels in breastfeeding and mixed-fed infants born to HIV-infected mothers living in resource-constrained settings, and to evaluate potential protective effects of calprotectin in early infancy, are recommended in the continuing effort to elucidate the mechanisms responsible for increased risk of HIV transmission through mixed-feeding.
Introduction

T
HE MECHANISM of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) through breastmilk is largely unknown. Intestinal inflammation and increased intestinal epithelial permeability of the infant gut resulting from ingestion of pathogen-laden food or water during mixed feeding has been proposed as one explanation. 1, 2 The impact of food antigens on physiologic changes in the intestinal mucosa and subsequent milk-borne HIV transmission is also unknown.
Intestinal biopsy would likely serve as the gold standard to test subclinical intestinal inflammation in vivo; however, a stable marker that could be detected in fecal samples would be a welcome surrogate for identifying intestinal inflammation. Calprotectin, a heterodimer also known as S100A8/A9, or myeloid-related protein-8/14, released primarily from neutrophils, 3 is detectable in fecal material and extremely stable at room temperature for several days. [3] [4] [5] Enzymelinked immunosorbent assay (ELISA) techniques have been utilized to measure fecal calprotectin concentrations, 6, 7 and commercial ELISA kits are now available. This protein has increased in popularity as a diagnostic screening marker for inflammatory bowel disease, ulcerative colitis, Crohn's disease, and colorectal neoplasia, because it reliably detects intestinal inflammation without the need for invasive techniques. [8] [9] [10] [11] [12] [13] We set out to determine in a prospective longitudinal pilot study whether mixed-feeding, compared to exclusive breastfeeding (EBF), in a population of healthy U.S. infants was associated with increased subclinical intestinal inflammation as measured by fecal calprotectin.
Subjects and Methods
Study population
Mothers were recruited from the Dartmouth Hitchcock Medical Center (DHMC) Women's Resource Center's Fourth Trimester Support Group. After being informed of the study by the group facilitator or the study coordinator, mothers who volunteered to contribute diapers were asked about their infants' feeding routines according to a specifically designed questionnaire. Information obtained at the time of sample collection included frequency of feeding of breastmilk and infant formula and/or weaning foods, types of formula or weaning food given, and administration of medications and vitamin/mineral supplements. Mothers were encouraged to donate multiple diapers until infants reached 6 months of age. 
Methods
Diapers were transported to the laboratory, where up to 2 mL of fecal material was transferred into sterile containers and stored at Ϫ70°C. Samples were later thawed at room temperature and analyzed for fecal calprotectin using the Phical ELISA commercial kit (developed by Calpro, Oslo, Norway; manufactured by Eurospital, Trieste, Italy; distributed by Genova Diagnostics, Ashville, NC). Results are expressed in mg/kg. According to the kit manufacturer, the reference median for healthy adults is 25 mg/kg, and values above 50 mg/kg are considered a positive indicator of intestinal inflammation.
Statistical analysis
To examine the association of fecal calprotectin with diet as well as with infant age, we employed a linear mixed-effects model, with fixed effects for age, EBF, EBF with medications/supplements, and mixed-feeding (breastmilk plus infant formula and/or weaning foods). Because of repeated measures, a random intercept was used for each infant. Analysis was carried out using the nlme library of R software (www.R-project.org).
Results
Seventy-seven fecal samples were obtained from 32 healthy term infants 3 days to 6 months old. Nineteen infants were boys, and 13 were girls. The ethnicity of all infants in the study was Caucasian, reflecting the demographics of the region near DHMC.
Forty-one samples were associated with EBF, 15 with EBF and medications/supplements, and 21 with mixed-feeding. Results from one sample obtained from a 6-week-old infant fed only formula (calprotectin concentration 180.23 mg/kg) were not included in the statistical analyses. Medications given to EBF infants within 24 hours of sample collection included simethicone (six samples), acetaminophen (one sample), and ranitidine (one sample). Supplements administered to EBF infants within 24 hours of sample collection consisted of various combinations of vitamins A, C, and D and/or iron (eight samples). One sample was collected from an infant given both vitamin drops and simethicone. Figure 1 depicts fecal calprotectin concentrations according to age and diet category. From 0 to 6 months, fecal calprotectin was negatively and significantly associated with age (p ϭ 0.014), declining on average 14 mg/kg (SE ϭ 6) per month. Mean calprotectin concentration for all samples (n ϭ 77) was 198 mg/kg (median ϭ 207, SD ϭ 77, range ϭ 23-359). In comparison to infants who were mixed-fed, and controlling for age, fecal calprotectin was significantly higher in the EBF group (p ϭ 0.01) by a mean of 60 mg/kg (SE ϭ 23) and also significantly higher in the group with EBF and medications or supplements (p ϭ 0.013) by a mean of 53 mg/kg (SE ϭ 21).
Discussion
We demonstrate in this pilot study of a healthy U.S. infant cohort through 6 months of age that fecal calprotectin concentrations from EBF infants or EBF infants receiving oral medications and/or vitamin/mineral supplements are higher than those from mixed-fed infants. We do not interpret these findings as increased intestinal inflammation in EBF infants, but rather as a lack of inflammation in mixedfed infants and perhaps a protective role for calprotectin in young EBF infants. Previous studies utilizing lactulose/mannitol ratios found no difference in intestinal epithelial permeability in South African infants who were either EBF or mixed-fed 14 or in a healthy cohort of Spanish infants who were either EBF or given one of four different infant formulas. 15 However, mixed-fed infants who ingest contaminated food or water might have higher fecal calprotectin concentrations than EBF infants.
Our study differs from previous similar studies in that we compared fecal calprotectin from EBF infants to that of infants receiving additional foods or supplements. Other studies have examined age-related fecal calprotectin levels in infants without stratifying according to diet 16 or assessed fecal calprotectin from EBF and weaning (mixed-fed) infants against those who were solely formula-fed. 17 Our study cohort did not have sufficient numbers of non-breastfed infants to include in our analysis. Thus, we are not able to directly compare our results with those from previously published studies.
Elevated concentrations of fecal calprotectin in healthy young infants found in our study as well as in previous stud-
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FIG. 1.
Fecal calprotectin concentrations (in mg/kg) classified according to infant age (by month) and diet category: EBF (E), EBF with medications or vitamin/mineral supplements (e), or breastmilk plus formula and/or solid food (mixed-fed) (m). ies of breastfed infants are similar to those of children and adults with inflammatory intestinal pathology. 10 We speculate that calprotectin may serve a protective role for the immature infant intestine, until epithelial tight junction proteins and other factors of intestinal immunity up-regulate with age. Calprotectin has demonstrated both bactericidal and fungicidal properties in vitro, 18 and its presence in the oral mucosa of HIV-infected individuals appears to prevent localized oral candidiasis from further dissemination. 19 The results of this study are unexpected. We hope that this report will foster additional exploration of the relative contributions of ingested and immunologic factors in elucidating the mechanism of HIV-1 transmission across the infant intestinal barrier.
